supernus pharmaceuticals inc - SUPN
SUPN
Close Chg Chg %
43.53 -1.10 -2.53%
Pre-Market
42.43
-1.10 (2.53%)
Volume: 429.13K
Last Updated:
Sep 8, 2026, 4:00 PM EDT
Company Overview: supernus pharmaceuticals inc - SUPN
SUPN Key Data
| Open $43.56 | Day Range 42.32 - 43.56 |
| 52 Week Range 42.32 - 59.68 | Market Cap $2.53B |
| Shares Outstanding 58.13M | Public Float 54.42M |
| Beta 0.56 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.91 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 565.14K |
SUPN Performance
| 1 Week | -2.53% | ||
| 1 Month | -10.94% | ||
| 3 Months | -4.46% | ||
| 1 Year | -6.67% | ||
| 5 Years | 59.57% |
SUPN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About supernus pharmaceuticals inc - SUPN
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
SUPN At a Glance
Supernus Pharmaceuticals, Inc.
9715 Key West Avenue
Rockville, Maryland 20850
| Phone | 1-301-838-2500 | Revenue | 718.95M | |
| Industry | Pharmaceuticals: Major | Net Income | -38,550,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 8.633% | |
| Fiscal Year-end | 12 / 2026 | Employees | 778 | |
| View SEC Filings |
SUPN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.902 |
| Price to Book Ratio | 2.69 |
| Price to Cash Flow Ratio | 59.28 |
| Enterprise Value to EBITDA | 46.654 |
| Enterprise Value to Sales | 3.53 |
| Total Debt to Enterprise Value | 0.016 |
SUPN Efficiency
| Revenue/Employee | 924,102.828 |
| Income Per Employee | -49,550.129 |
| Receivables Turnover | 3.178 |
| Total Asset Turnover | 0.462 |
SUPN Liquidity
| Current Ratio | 1.905 |
| Quick Ratio | 1.661 |
| Cash Ratio | 0.913 |
SUPN Profitability
| Gross Margin | 76.893 |
| Operating Margin | -5.169 |
| Pretax Margin | -6.82 |
| Net Margin | -5.362 |
| Return on Assets | -2.475 |
| Return on Equity | -3.676 |
| Return on Total Capital | -3.496 |
| Return on Invested Capital | -3.577 |
SUPN Capital Structure
| Total Debt to Total Equity | 3.86 |
| Total Debt to Total Capital | 3.716 |
| Total Debt to Total Assets | 2.539 |
| Long-Term Debt to Equity | 2.86 |
| Long-Term Debt to Total Capital | 2.754 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Supernus Pharmaceuticals Inc - SUPN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 667.24M | 607.52M | 661.82M | 718.95M | |
Sales Growth
| +15.09% | -8.95% | +8.94% | +8.63% | |
Cost of Goods Sold (COGS) incl D&A
| 172.85M | 168.64M | 158.32M | 166.13M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 85.63M | 84.86M | 80.41M | 91.56M | |
Depreciation
| 3.00M | 2.47M | 2.44M | 2.11M | |
Amortization of Intangibles
| 82.63M | 82.39M | 77.98M | 89.46M | |
COGS Growth
| +60.57% | -2.44% | -6.12% | +4.93% | |
Gross Income
| 494.39M | 438.88M | 503.50M | 552.83M | |
Gross Income Growth
| +4.72% | -11.23% | +14.72% | +9.80% | |
Gross Profit Margin
| +74.09% | +72.24% | +76.08% | +76.89% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 448.77M | 425.48M | 442.14M | 589.99M | |
Research & Development
| 71.55M | 89.12M | 106.36M | 104.13M | |
Other SG&A
| 377.22M | 336.36M | 335.78M | 485.86M | |
SGA Growth
| +20.99% | -5.19% | +3.92% | +33.44% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (510.00K) | 18.67M | (20.31M) | 25.12M | |
EBIT after Unusual Expense
| 46.12M | (5.27M) | 81.67M | (62.28M) | |
Non Operating Income/Expense
| 21.69M | 10.45M | 16.20M | 13.25M | |
Non-Operating Interest Income
| 21.69M | 10.45M | 16.20M | 13.25M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 7.07M | 2.42M | - |
Interest Expense Growth
| - | -69.82% | -65.84% | -100.00% | |
Gross Interest Expense
| - | - | 7.07M | 2.42M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 60.74M | 2.77M | 97.87M | (49.03M) | |
Pretax Income Growth
| -16.99% | -95.44% | +3,434.49% | -150.10% | |
Pretax Margin
| +9.10% | +0.46% | +14.79% | -6.82% | |
Income Tax
| 32.00K | 1.45M | 24.00M | (10.48M) | |
Income Tax - Current - Domestic
| 26.36M | 27.17M | 44.14M | (15.69M) | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (26.33M) | (25.71M) | (20.14M) | 5.25M | |
Income Tax - Deferred - Foreign
| - | - | - | (49.00K) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 60.71M | 1.32M | 73.86M | (38.55M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 60.71M | 1.32M | 73.86M | (38.55M) | |
Net Income Growth
| +13.64% | -97.83% | +5,512.84% | -152.19% | |
Net Margin Growth
| +9.10% | +0.22% | +11.16% | -5.36% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 60.71M | 1.32M | 73.86M | (38.55M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 60.71M | 1.32M | 73.86M | (38.55M) | |
EPS (Basic)
| 1.1313 | 0.0241 | 1.3406 | -0.6829 | |
EPS (Basic) Growth
| +12.44% | -97.87% | +5,462.66% | -150.94% | |
Basic Shares Outstanding
| 53.67M | 54.54M | 55.10M | 56.45M | |
EPS (Diluted)
| 1.042 | 0.0237 | 1.32 | -0.6829 | |
EPS (Diluted) Growth
| +6.02% | -97.73% | +5,469.62% | -151.73% | |
Diluted Shares Outstanding
| 61.68M | 55.51M | 55.96M | 56.45M | |
EBITDA
| 131.24M | 98.26M | 141.77M | 54.40M | |
EBITDA Growth
| -1.90% | -25.13% | +44.28% | -61.63% | |
EBITDA Margin
| +19.67% | +16.17% | +21.42% | +7.57% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 62.50 | |
| Number of Ratings | 4 | Current Quarters Estimate | 0.615 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | 2.565 | |
| Last Quarter’s Earnings | 0.526 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 3.235 | Next Fiscal Year Estimate | 4.46 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 2 | 2 |
| Mean Estimate | 0.62 | 1.09 | 2.57 | 4.46 |
| High Estimates | 0.62 | 1.27 | 2.65 | 4.55 |
| Low Estimate | 0.61 | 0.90 | 2.48 | 4.37 |
| Coefficient of Variance | 1.15 | 24.11 | 4.69 | 2.85 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 5 |
| OVERWEIGHT | 0 | 0 | 1 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Buy |
SEC Filings for Supernus Pharmaceuticals Inc - SUPN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Supernus Pharmaceuticals Inc - SUPN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 10, 2026 | Georges Gemayel Director | 28,159 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $53.71 per share | 1,512,419.89 |
| Mar 10, 2026 | Georges Gemayel Director | 36,064 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $25.3 per share | 912,419.20 |
| Mar 10, 2026 | Georges Gemayel Director | 27,277 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $53 per share | 1,445,681.00 |
| Mar 10, 2026 | Georges Gemayel Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2026 | Timothy C. Dec Senior Vice-President & CFO | 3,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2026 | Frank Mottola SVP, Chief Tech. Ops. Officer | 3,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2026 | Jack A. Khattar President, CEO; Director | 38,640 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2026 | Timothy C. Dec Senior Vice-President & CFO | 3,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Padmanabh P. Bhatt Sr. VP of IP, CSO | 17,694 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Frank Mottola SVP, Chief Tech. Ops. Officer | 1,875 | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Frank Mottola SVP, Chief Tech. Ops. Officer | 18,106 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $50.69 per share | 917,793.14 |
| Feb 27, 2026 | Jonathan Rubin SVP, Chief Medical Officer | 1,250 | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Jonathan Rubin SVP, Chief Medical Officer | 13,341 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $50.69 per share | 676,255.29 |
| Feb 27, 2026 | Jonathan Rubin SVP, Chief Medical Officer | 14,016 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Padmanabh P. Bhatt Sr. VP of IP, CSO | 1,250 | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Padmanabh P. Bhatt Sr. VP of IP, CSO | 17,044 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $50.69 per share | 863,960.36 |
| Feb 27, 2026 | Timothy C. Dec Senior Vice-President & CFO | 2,500 | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Jan 13, 2026 | Frederick M. Hudson Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 13, 2026 | Frederick M. Hudson Director | 61,307 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $12.98 per share | 795,764.86 |
| Dec 23, 2025 | Frank Mottola SVP, Chief Tech. Ops. Officer | 15,496 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.47 per share | 782,083.12 |